Givastomig is a monoclonal antibody commercialized by I-Mab, with a leading Phase I program in Gastric Cancer;Gastroesophageal (GE) Junction Carcinomas. According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Givastomig’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Givastomig is expected to reach an annual total of $48 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Givastomig Overview
I-Mab Overview
I-Mab is a biopharmaceutical company. It develops transformational medicines for therapeutic areas of immuno-oncology and autoimmune diseases. Its pipeline product portfolio comprises TJ202, a CD38 antibody for treating multiple myeloma; TJ101, a recombinant human growth hormone (rhGH) used in pediatric patients with growth hormone deficiency; TJ301, an IL-6 inhibitor for ulcerative colitis; enoblituzumab, a B7-H3 antibody against tumors; and TJ107, an oncology care agent to treat cancer treatment-related lymphopenia. I-Mab utilizes various molecular engineering platforms to develop drug molecules with defined biological properties. It operates in China, Hong Kong and the US. I-Mab is headquartered in Rockville, Maryland, the US.
The company reported revenues of (US Dollars) US$3.9 million for the fiscal year ended December 2023 (FY2023), compared to a revenue of US$31.2 million in FY2022. The operating loss of the company was US$197.7 million in FY2023, compared to an operating loss of US$276.9 million in FY2022. The net loss of the company was US$206.1 million in FY2023, compared to a net loss of US$352.5 million in FY2022.
For a complete picture of Givastomig’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
